ISRCTN72807124
Completed
Phase 3
A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanoma
Department of Health (UK)0 sites0 target enrollmentSeptember 12, 2003
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Stage IV melanoma
- Sponsor
- Department of Health (UK)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with resected stage IV melanoma.
Exclusion Criteria
- •Does not match inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A trial testing lenalidomide and dexamethasone after standard radiotherapy in patients with solitary bone plasmacytoma who are at a high risk of relapseEUCTR2015-001355-76-GBniversity College London140
Recruiting
Phase 3
Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAIRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300
Completed
Phase 1
Seasonal influenza vaccine study to determine the effect of an adjuvanted 2012 influenza vaccine in adultsPrevention of influenza infectionInfection - Other infectious diseasesPublic Health - Other public healthACTRN12612000709842Vaxine Pty Ltd200
Active, not recruiting
Phase 1
Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000
Completed
Phase 3
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecifiedCTRI/2009/091/000767Merck Sharp and Dohme2,800